

# Craig Coleman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9512072/craig-coleman-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

350  
papers

9,829  
citations

52  
h-index

83  
g-index

373  
ext. papers

11,269  
ext. citations

4.3  
avg, IF

6.35  
L-index

#	Paper	IF	Citations
350	Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.. <i>Current Medical Research and Opinion</i> , <b>2022</b> , 1-31	2.5	1
349	Patient Characteristics and Temporal Changes in Anticoagulation Treatment Patterns in Patients Diagnosed with Cancer-Associated Thrombosis: An Oscar-US Analysis. <i>Blood</i> , <b>2021</b> , 138, 2132-2132	2.2	
348	Thromboembolism, Bleeding, and Vascular Death Among Older and Younger Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin. <i>Blood</i> , <b>2021</b> , 138, 3234-3234 <sup>2</sup>	2.2	2
347	Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 1-8	2.5	
346	Welcome to the cardiovascular outcomes trials issue. <i>Future Cardiology</i> , <b>2021</b> , 17, 399-402	1.3	1
345	Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1493-1500	2.5	
344	Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. <i>Future Cardiology</i> , <b>2021</b> , 17, 127-135	1.3	9
343	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 349-358	5.1	8
342	Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 52	8.7	4
341	Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 135, 170-175	5.7	1
340	Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 1-8	2.5	
339	Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review. <i>BMJ Open</i> , <b>2020</b> , 10, e040499	3	6
338	Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 524-531	3.3	10
337	Physicians' perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey. <i>PLoS ONE</i> , <b>2020</b> , 15, e0225867	3.7	7
336	Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014402	6	26
335	Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. <i>PLoS ONE</i> , <b>2020</b> , 15, e0225301	3.7	7
334	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1081-1088 <sup>2</sup>	2.5	19

333	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , <b>2020</b> , 4, e344-e350	2.7	
332	Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting. <i>Prehospital Emergency Care</i> , <b>2020</b> , 24, 163-174	2.8	15
331	Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 328-335	3.8	17
330	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620954910	3.3	1
329	Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1077-1086	3.5	2
328	Specialist physician perspectives on non-medical switching of prescription medications. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1738637	3.7	3
327	Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation. <i>Journal of the National Medical Association</i> , <b>2020</b> , 112, 395-401	2.3	1
326	REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2209	15.1	4
325	Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1829883	3.7	2
324	Burden-of-Illness Associated with Bleeding-Related Hospitalizations in Atrial Fibrillation Patients: Findings from the Nationwide Readmission Database. <i>TH Open</i> , <b>2020</b> , 4, e211-e217	2.7	1
323	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. <i>Blood Advances</i> , <b>2020</b> , 4, 4045-4051	7.8	0
322	Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. <i>Heart Rhythm</i> , <b>2020</b> , 17, e206-e219	6.7	19
321	Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 44-52	3.5	3
320	Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2020</b> , 6, 301-307	4.6	19
319	Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> , 6, 159-166	6.4	13
318	Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. <i>Thrombosis Journal</i> , <b>2020</b> , 18, 6	5.6	2
317	Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 366-372	5.1	2
316	Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. <i>Journal of the American Geriatrics Society</i> , <b>2019</b> , 67, 1571-1581	5.6	28

315	Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 1078-1083	2.4	60
314	Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample. <i>Atherosclerosis</i> , <b>2019</b> , 286, 142-146	3.1	15
313	Treatment patterns, glycemic control and bodyweight with canagliflozin 300mg versus GLP1RAs in Type II diabetes patients. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 889-905	2.1	4
312	Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619850897	3.3	14
311	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2107-2114	6.7	21
310	Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. <i>Journal of Medical Economics</i> , <b>2019</b> , 22, 751-759	2.4	5
309	Can apixaban prevent venous thromboembolism better than rivaroxaban?. <i>Lancet Haematology</i> , <b>2019</b> , 6, e179	14.6	
308	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 149-157	5.1	9
307	External validation of three risk stratification rules in patients presenting with pulmonary embolism and cancer. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 921-925	3.9	2
306	Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 64-69	6.4	13
305	Rivaroxaban® Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 107602961985335	3.3	20
304	Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1867-1872	2.5	6
303	Outcomes of Hemorrhagic Stroke Patients with Atrial Fibrillation or Flutter. <i>Journal of Atrial Fibrillation</i> , <b>2019</b> , 11, 2144	0.8	1
302	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. <i>Journal of Health Economics and Outcomes Research</i> , <b>2019</b> , 6, 84-94	1.6	2
301	Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis. <i>Blood</i> , <b>2019</b> , 134, 3673-3673	2.3	23
300	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. <i>Journal of Health Economics and Outcomes Research</i> , <b>2019</b> , 6, 160-173	1.6	0
299	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1574541	3.7	21
298	P4778 Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease. <i>European Heart Journal</i> , <b>2019</b> , 40,	9.5	1

297	Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. <i>BMJ Open Diabetes Research and Care</i> , <b>2019</b> , 7, e000704	4.5	5
296	AHRQ Series on Improving Translation of Evidence: Linking Evidence Reports and Performance Measures to Help Learning Health Systems Use New Information for Improvement. <i>Joint Commission Journal on Quality and Patient Safety</i> , <b>2019</b> , 45, 706-710	1.4	2
295	The impact of non-medical switching among ambulatory patients: an updated systematic literature review. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1678563	3.7	5
294	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 27-36	2.2	13
293	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 498-504	2.4	3
292	Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 196-203	5.8	11
291	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 143-149	3.8	3
290	Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 10-15	3.7	5
289	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 787-794.e4	2.4	13
288	The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1081-1087	2.5	4
287	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 575-582	3.3	14
286	The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1501-1511	2.5	4
285	Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. <i>Diabetic Medicine</i> , <b>2018</b> , 35, 1105-1110	3.5	21
284	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	56
283	Meta-Analysis of Time in Therapeutic Range in Continuous-Flow Left Ventricular Assist Device Patients Receiving Warfarin. <i>Artificial Organs</i> , <b>2018</b> , 42, 700-704	2.6	22
282	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , <b>2018</b> , 163, 132-137	8.2	5
281	Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2018</b> , 4, 328-329	4.6	8
280	Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 119-125	3.3	3

279	Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 610-618	5.8	6
278	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, S45-S60	7	7
277	Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1473-1484	27.4	54
276	Association of Inhaled Corticosteroids and Long-Acting $\beta$ -Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1485-1496	27.4	129
275	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 933-938.e1	2.4	13
274	Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. <i>Heart Lung and Circulation</i> , <b>2018</b> , 27, 390-393	1.8	6
273	Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. <i>Journal of Diabetes and Its Complications</i> , <b>2018</b> , 32, 210-215	3.2	18
272	Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 1141-1149	3.7	5
271	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. <i>Thrombosis Research</i> , <b>2018</b> , 168, 31-36	8.2	8
270	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 339-345	5.1	10
269	Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191657	3.7	7
268	Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis. <i>Journal of Innovations in Cardiac Rhythm Management</i> , <b>2018</b> , 9, 3151-3162	1.1	8
267	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study. <i>Blood</i> , <b>2018</b> , 132, 1241-1241	2.2	
266	Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 275-284	2.5	1
265	Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 279-292	15.4	8
264	P4813 Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure. <i>European Heart Journal</i> , <b>2018</b> , 39,	9.5	1
263	Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 2125-2130	2.5	16
262	Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. <i>International Journal of Cardiology</i> , <b>2018</b> , 273, 34-38	3.2	2

261	Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 1825-1875	3.3	24
260	Emergency Department Discharge of Pulmonary Embolus Patients. <i>Academic Emergency Medicine</i> , <b>2018</b> , 25, 995-1003	3.4	29
259	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 491-497	7.3	11
258	CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1967-1974	2.5	
257	External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 769-774	3.3	14
256	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. <i>International Journal of Clinical Practice</i> , <b>2017</b> , 71, e12915	2.9	2
255	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 613-619	3.7	3
254	Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 419-422	3.7	9
253	Importance of balancing follow-up time and impact of oral-anticoagulant users selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1033-1043	2.5	6
252	External validation of the multivariable Q <sub>h</sub> -hospital Mortality for Pulmonary embolism using Claims data: a prediction rule in the Premier Hospital Database. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2017</b> , 3, 157-159	4.6	2
251	External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and Active Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 1476-1482	7.3	4
250	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1426-1436.e2	3.5	2
249	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , <b>2017</b> , 48, 2142-2149	6.7	70
248	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 37	3.5	1
247	Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1697-1703	2.5	6
246	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 311-318	3.7	11
245	Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 200-203	2.4	13
244	Association between weekend admission and mortality for upper gastrointestinal hemorrhage: an observational study and meta-analysis. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 163-169	3.7	7

243	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 830-837	3.3	13
242	Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1841-1847	7	25
241	Credentials of Professionals Performing Echocardiography: Insights From the Intersocietal Accreditation Commission-Echocardiography Database. <i>Journal of Diagnostic Medical Sonography</i> , <b>2017</b> , 33, 91-99	0.4	1
240	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185022	5.7	9
239	Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. <i>Pharmacotherapy</i> , <b>2016</b> , 36, 1109-1115	5.8	12
238	Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 2047-2053	2.5	75
237	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 565-569	3.3	27
236	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 513-9	5.1	3
235	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, S13-S23	7	31
234	Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2016</b> , 152, 1142-53	1.5	32
233	AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis: Importance for Individual Patient Outcomes. <i>Clinical Journal of Sport Medicine</i> , <b>2016</b> , 26, 1-11	3.2	37
232	External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches. <i>Thrombosis Journal</i> , <b>2016</b> , 14, 7	5.6	10
231	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. <i>Thrombosis Journal</i> , <b>2016</b> , 14, 14	5.6	27
230	Outcomes related to variation in hospital pulmonary embolus observation stay utilization. <i>Hospital Practice (1995)</i> , <b>2016</b> , 44, 133-7	2.2	1
229	Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1281-90	2.5	30
228	REal-Life Evidence of stroke prevention in patients with atrial Fibrillation--The RELIEF study. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 882-4	3.2	32
227	Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1277-9	2.5	18
226	External validation of the In-hospital Mortality for PulmonARy embolism using Claims daTa (IMPACT) multivariable prediction rule. <i>International Journal of Clinical Practice</i> , <b>2016</b> , 70, 82-8	2.9	5

225	Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. <i>Thrombosis Research</i> , <b>2016</b> , 141, 8-10	8.2	4
224	Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1117-20	2.5	12
223	AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes. <i>British Journal of Sports Medicine</i> , <b>2016</b> , 50, 84-92	10.3	49
222	Association between weekend admission for atrial fibrillation or flutter and in-hospital mortality, procedure utilization, length-of-stay and treatment costs. <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 427-9	3.2	9
221	Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157769 <sup>27</sup>	3.7	27
220	Appraising Evidence <b>2016</b> , 115-135		1
219	External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer. <i>Blood</i> , <b>2016</b> , 128, 4730-4730 <sup>2,2</sup>		2,2
218	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. <i>Blood</i> , <b>2016</b> , 128, 533-533	2.2	
217	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. <i>Blood</i> , <b>2016</b> , 128, 2337-2337	2.2	
216	Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. <i>Patient Related Outcome Measures</i> , <b>2016</b> , 7, 13-8	2.9	2
215	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <i>Pharmacotherapy</i> , <b>2016</b> , 36, 488-95	5.8	13
214	Quality measures for anticoagulation care. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1685-1692	2.5	2
213	Prescribers' behavior following below- versus above-range international normalized ratio values in warfarin-treated deep vein thrombosis patients. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1213-5 <sup>2.5</sup>		2.5
212	External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. <i>BMC Health Services Research</i> , <b>2016</b> , 16, 610	2.9	3
211	Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 2056-2066	2.2	17
210	Association between weekend admission for intracerebral and subarachnoid hemorrhage and in-hospital mortality. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 26-8	3.2	3
209	Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. <i>International Journal of Cardiology</i> , <b>2016</b> , 215, 11-3	3.2	38
208	Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 171-3	3.2	28

207	Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 104-9	3.2	30
206	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. <i>International Journal of Cardiology</i> , <b>2016</b> , 222, 846-849	3.2	1
205	Association between weekend admission and in-hospital mortality for pulmonary embolism: An observational study and meta-analysis. <i>International Journal of Cardiology</i> , <b>2015</b> , 194, 72-4	3.2	11
204	Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis. <i>Thrombosis Research</i> , <b>2015</b> , 135, 888-96	8.2	27
203	Corrected QT in ventricular paced rhythms: what is the validation for commonly practiced assumptions?. <i>Cardiology</i> , <b>2015</b> , 130, 207-10	1.6	13
202	Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125879	3.7	98
201	Derivation and validation of the In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1461-8	2.5	13
200	Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1831-40	2.5	21
199	Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 1221-35	2.9	15
198	Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1043-52	15.4	14
197	Validation of the multivariable In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule within an all-payer inpatient administrative claims database. <i>BMJ Open</i> , <b>2015</b> , 5, e009251	3	14
196	Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. <i>Chest</i> , <b>2015</b> , 147, 1043-1062	5.3	62
195	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <i>Diabetic Medicine</i> , <b>2015</b> , 32, 1530-40	3.5	33
194	Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know?. <i>Europace</i> , <b>2015</b> , 17, 1316-7	3.9	1
193	Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective. <i>BMJ Open</i> , <b>2015</b> , 5, e008861	3	5
192	Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial. <i>Open Cardiovascular Medicine Journal</i> , <b>2015</b> , 9, 83-8	0.7	3
191	Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database. <i>Blood</i> , <b>2015</b> , 126, 747-747	2.2	
190	Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?. <i>Blood</i> , <b>2015</b> , 126, 2058-2058	2.2	

189	Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1306-11	3	11
188	Walking speed and health-related quality of life in multiple sclerosis. <i>Patient</i> , <b>2014</b> , 7, 55-61	3.7	22
187	Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 52-64	2.4	56
186	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 1093-102	5.7	9
185	Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. <i>Thrombosis Journal</i> , <b>2014</b> , 12, 14	5.6	76
184	Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , <b>2014</b> , 12, 66	3	21
183	Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1317-25	2.5	153
182	Inferior vena cava filters and postoperative outcomes in patients undergoing bariatric surgery: a meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , <b>2014</b> , 10, 725-33	3	34
181	Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. <i>Thrombosis Research</i> , <b>2014</b> , 134, 310-9	8.2	33
180	Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 103-10	7	6
179	The prognostic impact of pre-implantation hyponatremia on morbidity and mortality among patients with left ventricular dysfunction and implantable cardioverter-defibrillators. <i>Europace</i> , <b>2014</b> , 16, 47-54	3.9	5
178	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. <i>BMJ Open</i> , <b>2014</b> , 4, e005379	3	1
177	Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1513-20	2.5	16
176	The healthcare utilization and cost of treating patients experiencing inappropriate implantable cardioverter defibrillator shocks: a propensity score study. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2014</b> , 37, 1315-23	1.6	15
175	Mobility, walking and physical activity in persons with multiple sclerosis. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1857-62	2.5	11
174	Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 2461-9	2.5	71
173	Impact of angina frequency on health utility values of patients with chronic stable angina. <i>Health and Quality of Life Outcomes</i> , <b>2014</b> , 12, 39	3	5
172	Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. <i>Thrombosis Research</i> , <b>2014</b> , 133, 743-9	8.2	16

171	Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism. <i>Blood</i> , <b>2014</b> , 124, 4832-4832	2.2	
170	Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. <i>Health and Quality of Life Outcomes</i> , <b>2013</b> , 11, 105	3	15
169	Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients. <i>Annals of Noninvasive Electrocardiology</i> , <b>2013</b> , 18, 379-88	1.5	18
168	Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 355-62	3	19
167	The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2013</b> , 36, 878-84	1.6	21
166	Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , <b>2013</b> , 132, 420-6	8.2	32
165	Gender differences in the diagnostic accuracy of SPECT myocardial perfusion imaging: a bivariate meta-analysis. <i>Journal of Nuclear Cardiology</i> , <b>2013</b> , 20, 53-63	2.1	29
164	Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. <i>PLoS ONE</i> , <b>2013</b> , 8, e62183	3.7	44
163	Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. <i>Journal of Investigative Medicine</i> , <b>2013</b> , 61, 878-81	2.9	19
162	Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients. <i>BMJ Open</i> , <b>2013</b> , 3,	3	9
161	Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review. <i>BMJ Open</i> , <b>2013</b> , 3,	3	25
160	College and school of pharmacy characteristics associated with US News and World Report rankings. <i>American Journal of Pharmaceutical Education</i> , <b>2013</b> , 77, 55	2.5	9
159	Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 90-4	1.7	25
158	Comparative effectiveness of combined pharmacologic and mechanical thromboprophylaxis versus either method alone in major orthopedic surgery: a systematic review and meta-analysis. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 275-83	5.8	13
157	Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. <i>Annals of Family Medicine</i> , <b>2013</b> , 11, 452-9	2.9	148
156	Use of preoperative CHA2 DS2 -VASc score to predict the risk of atrial fibrillation after cardiothoracic surgery: a nested case-control study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 489-95	5.8	9
155	Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e54756	3.7	31
154	Short-term consequences of angiographically-confirmed coronary stent thrombosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e77330	3.7	5

153	Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. <i>BMC Family Practice</i> , <b>2012</b> , 13, 5	2.6	70
152	Factors associated with caregiver burden for atrial fibrillation patients. <i>International Journal of Clinical Practice</i> , <b>2012</b> , 66, 984-90	2.9	13
151	Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. <i>Dermatology and Therapy</i> , <b>2012</b> , 2, 9	4	28
150	Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. <i>Circulation: Cardiovascular Imaging</i> , <b>2012</b> , 5, 700-7	3.9	144
149	Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 49-56	2.5	59
148	Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 845-51	3	113
147	Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. <i>Pharmacotherapy</i> , <b>2012</b> , 32, 799-808	5.8	23
146	Assessing equivalence and noninferiority. <i>Journal of Clinical Epidemiology</i> , <b>2012</b> , 65, 1144-9	5.7	36
145	The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: a systematic review. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, 1220-31	2.9	5
144	Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. <i>Journal of Medical Economics</i> , <b>2012</b> , 15, 1088-96	2.4	31
143	Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. <i>PLoS ONE</i> , <b>2012</b> , 7, e47473	3.7	55
142	Dosing frequency and medication adherence in chronic disease. <i>Journal of Managed Care Pharmacy</i> , <b>2012</b> , 18, 527-39		234
141	Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. <i>Pharmacotherapy</i> , <b>2012</b> , 32, 314-22	5.8	25
140	Chapter 8: meta-analysis of test performance when there is a "gold standard". <i>Journal of General Internal Medicine</i> , <b>2012</b> , 27 Suppl 1, S56-66	4	59
139	Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. <i>International Journal of Clinical Practice</i> , <b>2012</b> , 66, 53-63	2.9	49
138	Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. <i>International Journal of Clinical Practice</i> , <b>2012</b> , 66, 171-82	2.9	18
137	Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1020-5	3	13
136	CRT-D Therapy in Patients with Decompensated NYHA Class-Four CHF. <i>Cardiology Research and Practice</i> , <b>2012</b> , 2012, 319205	1.9	2

135	The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. <i>American Journal of Therapeutics</i> , <b>2012</b> , 19, 16-23	1	11
134	Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 1494-9	2.2	21
133	Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, 469-76	2.9	21
132	Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 472-9	5.8	29
131	Effect of dosing frequency on chronic cardiovascular disease medication adherence. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 669-80	2.5	95
130	Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. <i>Annals of Internal Medicine</i> , <b>2012</b> , 156, 720-7	8	26
129	Association between CHADS <sub>2</sub> risk factors and anticoagulation-related bleeding: a systematic literature review. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, 509-21	6.4	13
128	Predictors of poor student performance at a single, Accreditation Council for Pharmacy Education-accredited school of pharmacy. <i>Currents in Pharmacy Teaching and Learning</i> , <b>2011</b> , 3, 101-105	1.5	17
127	Systematic review: comparative effectiveness of adjunctive devices in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention of native vessels. <i>BMC Cardiovascular Disorders</i> , <b>2011</b> , 11, 74	2.3	5
126	Effect of pharmacist intervention on glycemic control in diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2011</b> , 92, 145-52	7.4	56
125	Updating comparative effectiveness reviews: current efforts in AHRQ's Effective Health Care Program. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 1208-15	5.7	19
124	Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 243-52	8	64
123	Intent to update systematic reviews: results of an internet survey. <i>Journal of Investigative Medicine</i> , <b>2011</b> , 59, 811-5	2.9	
122	Oral anti-diabetic drugs for the prevention of Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2011</b> , 28, 948-64	3.5	23
121	Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review. <i>International Journal of Clinical Practice</i> , <b>2011</b> , 65, 749-63	2.9	3
120	The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. <i>Journal of the American Dietetic Association</i> , <b>2011</b> , 111, 1173-81		114
119	Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. <i>Journal of the American Dietetic Association</i> , <b>2011</b> , 111, 1720-9		115
118	Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery. <i>American Journal of Health-System Pharmacy</i> , <b>2011</b> , 68, 1632-9	2.2	25

117	IntravenousCorticosteroid Use Is Associated With Reduced Early Recurrence of Atrial Fibrillation Immediately Following Radiofrequency Catheter Ablation. <i>Journal of Atrial Fibrillation</i> , <b>2011</b> , 4, 349	0.8	1
116	US prevalence of upper gastrointestinal symptoms: a systematic literature review. <i>American Journal of Managed Care</i> , <b>2011</b> , 17, e449-58	2.1	19
115	Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1239-44	2.9	30
114	Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1116-20	2.9	13
113	Statin use and the prevention of venous thromboembolism: a meta-analysis. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1375-83	2.9	50
112	Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1410-8	27.4	370
111	Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2010</b> , 44, 471-8	2.9	29
110	Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 DiabetesReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 405	27.4	
109	Benefits and risks associated with beta-blocker prophylaxis in noncardiac surgery. <i>American Journal of Health-System Pharmacy</i> , <b>2010</b> , 67, 523-30	2.2	8
108	Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition. <i>American Journal of Health-System Pharmacy</i> , <b>2010</b> , 67, 535-41	2.2	14
107	Recombinant human growth hormone in the treatment of patients with cystic fibrosis. <i>Pediatrics</i> , <b>2010</b> , 126, e1211-26	7.4	28
106	Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , <b>2010</b> , 91, 73-81	7	135
105	The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , <b>2010</b> , 7, 755-60	6.7	40
104	Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2010</b> , 87, 98-107	7.4	137
103	Contribution of intangible costs to the economic burden of multiple sclerosis. <i>Journal of Medical Economics</i> , <b>2010</b> , 13, 626-32	2.4	20
102	Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2010</b> , 140, 364-72	1.5	67
101	The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. <i>Journal of the American Dietetic Association</i> , <b>2010</b> , 110, 719-26		71
100	The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1286-92	4.6	38

99	Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. <i>Journal of Managed Care Pharmacy</i> , <b>2009</b> , 15, 244-52		286
98	Reducing adverse self-medication behaviors in older adults with the Next Generation Personal Education Program (PEP-NG): Design and methodology. <i>Patient Preference and Adherence</i> , <b>2009</b> , 3, 323-344		7
97	Outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery: a meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 1181-8	2.9	20
96	The impact of garlic on lipid parameters: a systematic review and meta-analysis. <i>Nutrition Research Reviews</i> , <b>2009</b> , 22, 39-48	7	70
95	Assessing the usefulness of health-related quality-of-life trials: a clinician@ perspective using two COPD examples. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 1496-505	2.9	3
94	The effects of barley-derived soluble fiber on serum lipids. <i>Annals of Family Medicine</i> , <b>2009</b> , 7, 157-63	2.9	79
93	Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. <i>Europace</i> , <b>2009</b> , 11, 892-5	3.9	17
92	Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 569-76	2.9	7
91	The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. <i>Journal of the American College of Nutrition</i> , <b>2009</b> , 28, 517-24	3.5	53
90	Letter by Baker et al regarding article, "benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis". <i>Circulation</i> , <b>2009</b> , 120, e163	16.7	2
89	Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 813-21	2.9	7
88	Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 891-905	5.8	37
87	A clinician@ perspective on rating the strength of evidence in a systematic review. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1017-29	5.8	6
86	Almonds have a neutral effect on serum lipid profiles: a meta-analysis of randomized trials. <i>Journal of the American Dietetic Association</i> , <b>2009</b> , 109, 865-73		58
85	Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson@ disease: a meta analysis. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 613-23	2.9	28
84	Understanding heterogeneity in meta-analysis: the role of meta-regression. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1426-34	2.9	226
83	Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2009</b> , 35, 521-7	3	66
82	The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2009</b> , 84, e33-7	7.4	30

81	Dopamine agonists in the treatment of early Parkinson disease: a meta-analysis. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15, 287-94	3.6	46
80	Pharmacologic treatment of advanced Parkinson disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15, 500-5	3.6	24
79	A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. <i>Annals of Nutrition and Metabolism</i> , <b>2009</b> , 55, 368-74	4.5	31
78	Feverfew for migraine prophylaxis: a systematic review. <i>Journal of Dietary Supplements</i> , <b>2009</b> , 6, 91-103	2.3	14
77	The association among blood transfusions, white blood cell count, and the frequency of post-cardiothoracic surgery atrial fibrillation: a nested cohort study from the Atrial Fibrillation Suppression Trials I, II, and III. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2009</b> , 23, 22-7	2.1	20
76	Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. <i>American Journal of Health-System Pharmacy</i> , <b>2009</b> , 66, 916-25	2.2	31
75	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 861-71	2.8	29
74	The impact of biologic agents to treat plaque psoriasis. <i>Connecticut Medicine</i> , <b>2009</b> , 73, 79-83		
73	Status epilepticus: a review of current pharmacologic treatments. <i>Connecticut Medicine</i> , <b>2009</b> , 73, 525-8		1
72	Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2008</b> , 135, 405-11	1.5	76
71	Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. <i>Journal of Critical Care</i> , <b>2008</b> , 23, 91-100	4	125
70	Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. <i>Clinical Therapeutics</i> , <b>2008</b> , 30, 1416-25	3.5	28
69	Benefit of echinacea for the prevention and treatment of the common cold? [Author reply]. <i>Lancet Infectious Diseases</i> , <b>2008</b> , 8, 347-348	25.5	
68	Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. <i>Heart Rhythm</i> , <b>2008</b> , 5, 507-10	6.7	17
67	Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 1766-71	2.9	105
66	The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 1359-62	2.5	63
65	Impact of amiodarone on the ability of anterior fat pad retention to prevent postcoronary arterial bypass grafting atrial fibrillation incidence: a substudy of the AFIST III (Atrial Fibrillation Suppression Trial III). <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 7-13	4	
64	Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. <i>Europace</i> , <b>2008</b> , 10, 854-9	3.9	22

63	Effect of cinnamon on glucose control and lipid parameters. <i>Diabetes Care</i> , <b>2008</b> , 31, 41-3	14.6	99
62	Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. <i>Annals of Family Medicine</i> , <b>2008</b> , 6, 253-62	2.9	22
61	Association between perioperative NSAID use and post-cardiothoracic surgery atrial fibrillation, blood transfusions, and cardiovascular outcomes: a nested cohort study from the AF Suppression Trials (AFIST) I, II and III. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 1131-6	2.5	10
60	Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 622-9	1.9	63
59	Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , <b>2008</b> , 88, 1167-75	7	122
58	The role of soluble fiber in the management of patients with hypercholesterolemia: a review of the literature. <i>Connecticut Medicine</i> , <b>2008</b> , 72, 465-8		1
57	Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. <i>Heart Rhythm</i> , <b>2007</b> , 4, 461-8	6.7	45
56	Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 298-303	15.1	45
55	Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. <i>Diabetic Medicine</i> , <b>2007</b> , 24, 486-93	3.5	100
54	Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2007</b> , 30, 1331-5	1.6	35
53	Evaluating the safety implications of aprotinin use: the Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS). <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2007</b> , 133, 1547-52	1.5	20
52	Preoperative statins and infectious complications following cardiac surgery. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 1783-90	2.5	62
51	The use of protamine after radiofrequency catheter ablation: a pilot study. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2007</b> , 18, 155-8	2.4	15
50	Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 433-7	2.9	29
49	Impact of gender on statin efficacy. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 565-74	2.5	40
48	Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2849-55	2.5	19
47	The relationship between statin use and atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 1177-85	2.5	31
46	Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2007</b> , 31, 817-20	3	51

45	Number and impact of published scholarly works by pharmacy practice faculty members at accredited US colleges and schools of pharmacy (2001-2003). <i>American Journal of Pharmaceutical Education</i> , <b>2007</b> , 71, 44	2.5	30
44	Impact of statin dosing intensity on transaminase and creatine kinase. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 706-12	2.4	40
43	Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. <i>Lancet Infectious Diseases, The</i> , <b>2007</b> , 7, 473-80	25.5	122
42	Journal publications by pharmacy practice faculty evaluated by institution and region of the United States (2001-2003). <i>Pharmacy Practice</i> , <b>2007</b> , 5, 151-6	1.8	7
41	A comparison of different protease inhibitors on coronary heart disease risk. <i>Connecticut Medicine</i> , <b>2007</b> , 71, 15-7		1
40	Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. <i>Connecticut Medicine</i> , <b>2007</b> , 71, 93-5		4
39	Comparative safety and efficacy of urokinase and recombinant tissue plasminogen activator for peripheral arterial occlusion: a meta-analysis. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 51-60	5.8	2
38	Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 499-504	5.8	9
37	Statins and cancer risk: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 74-80	27.4	447
36	Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. <i>American Journal of Health-System Pharmacy</i> , <b>2006</b> , 63, 829-37	2.2	47
35	Delivery of esomeprazole magnesium through nasogastric and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro. <i>American Journal of Health-System Pharmacy</i> , <b>2006</b> , 63, 1882-7	2.2	4
34	The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 464-72	3.3	124
33	The impact of suppressing the renin-angiotensin system on atrial fibrillation. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 21-8	2.9	42
32	Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals. <i>Clinical Therapeutics</i> , <b>2006</b> , 28, 1054-62	3.5	9
31	An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. <i>Annals of Noninvasive Electrocardiology</i> , <b>2006</b> , 11, 163-9	1.5	15
30	The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. <i>Journal of Internal Medicine</i> , <b>2006</b> , 260, 467-73	10.8	24
29	Impact of Hispanic ethnicity on the likelihood of developing postoperative atrial fibrillation. <i>Connecticut Medicine</i> , <b>2006</b> , 70, 77-9		
28	The effect of Echinacea on upper respiratory infection symptom severity and quality of life. <i>Connecticut Medicine</i> , <b>2006</b> , 70, 93-7		4

27	The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 2261-6	14.6	174
26	A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1963-9	3.5	15
25	Impact of intravenous magnesium on post-cardiothoracic surgery atrial fibrillation and length of hospital stay: a meta-analysis. <i>Annals of Thoracic Surgery</i> , <b>2005</b> , 80, 2402-6	2.7	41
24	Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 320-4	5.8	11
23	Probable topical permethrin-induced neck dystonia. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 448-50	5.8	17
22	Cost-Effectiveness Analysis of Combination Statin/Ezetimibe Therapy for the Treatment of Elevated Low-Density Lipoprotein Cholesterol. <i>Hospital Pharmacy</i> , <b>2005</b> , 40, 687-692	1.1	0
21	Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 1409-15	2.9	25
20	Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. <i>American Journal of Health-System Pharmacy</i> , <b>2005</b> , 62, 1370-4	2.2	6
19	Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. <i>Connecticut Medicine</i> , <b>2005</b> , 69, 19-22		1
18	Atazanavir: a new protease inhibitor to treat HIV infection. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 1365-74	2.2	18
17	Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 685-8	2.2	5
16	Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. <i>Annals of Pharmacotherapy</i> , <b>2004</b> , 38, 2012-6	2.9	36
15	Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 216-21	27.4	70
14	Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 1013-9	5.8	6
13	Alendronate-induced auditory hallucinations and visual disturbances. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 799-802	5.8	11
12	Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 877-83	4.4	7
11	Indicators of atrial fibrillation risk in cardiac surgery patients on prophylactic amiodarone. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 77, 1288-92	2.7	29
10	Can a multidisciplinary initiative to increase adverse drug reaction reporting work?. <i>Connecticut Medicine</i> , <b>2004</b> , 68, 281-4		1

9	Effect of practitioner education on adherence to asthma treatment guidelines. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 956-61	2.9	9
8	Cost-benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients. <i>American Journal of Health-System Pharmacy</i> , <b>2003</b> , 60, 378-82	2.2	9
7	Prescriber and pharmacist responses to intervention letters for Connecticut Medicaid beneficiaries with asthma. <i>American Journal of Health-System Pharmacy</i> , <b>2003</b> , 60, 1142-4	2.2	
6	The effects of Panax ginseng on quality of life. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2003</b> , 28, 5-15	2.2	87
5	The effect of phytosterols on quality of life in the treatment of benign prostatic hyperplasia. <i>Pharmacotherapy</i> , <b>2002</b> , 22, 1426-32	5.8	6
4	Possible gatifloxacin-induced fulminant hepatic failure. <i>Annals of Pharmacotherapy</i> , <b>2002</b> , 36, 1162-7	2.9	32
3	Budesonide: its role in Crohn's disease therapy. <i>Connecticut Medicine</i> , <b>2002</b> , 66, 523-6		
2	A medication assistance program to increase access to health-care. <i>Connecticut Medicine</i> , <b>2001</b> , 65, 711-3		
1	Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting		4